or Try an Advanced Search...

    Chimeric Antigen Receptor T Cell Stocks List

    Symbol Grade Name % Change
    PSTX C Poseida Therapeutics, Inc. 3.08
    SNTI C Senti Biosciences, Inc. 51.27
    JANX C Janux Therapeutics, Inc. -0.41
    CARM D Carisma Therapeutics, Inc. 9.87
    NTLA D Intellia Therapeutics, Inc. 0.40
    NKTX F Nkarta, Inc. -1.02
    TSVT F 2seventy bio, Inc. 5.19
    GDTC F CytoMed Therapeutics Limited -3.85
    ACET F Adicet Bio, Inc. -4.96
    CRBU F Caribou Biosciences, Inc. -3.05
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Medicine Immune System Biopharmaceutical Biotechnology Cancer Chimeric Antigen Receptor Clinical Medicine Solid Tumors Antigen Biology Cancer Immunotherapy Cancer Treatment Cell Therapy Life Sciences Natural Killer Cell Breakthrough Therapy CD19 Disease Emerging Technologies Gene Therapy

    Related ETFs - A few ETFs which own one or more of the above listed Chimeric Antigen Receptor T Cell stocks.

    Symbol Grade Name Weight
    GNOM C Global X Genomics & Biotechnology ETF 5.53
    ARKG F ARK Genomic Revolution Multi-Sector ETF 4.65
    CNCR D Loncar Cancer Immunotherapy ETF 4.63
    ARKK C ARK Innovation ETF 3.37
    MOON D Direxion Moonshot Innovators ETF 1.92
    View all Chimeric Antigen Receptor T Cell ETFs...
    Compare ETFs
    Compare ARKG to MOON Compare CNCR to ARKK Compare GNOM to ARKK

        Chimeric Antigen Receptor T Cell Stocks Recent News

        Date Stock Title
        Jul 1 PSTX Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
        Jul 1 SNTI Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
        Jul 1 SNTI Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
        Jun 28 CARM Carisma jumps as drug discovery under Moderna deal leads to $2M payment
        Jun 27 CARM Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
        Jun 27 NTLA Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
        Jun 27 TSVT Novo Nordisk buys 2seventy bio’s Hemophilia A program
        Jun 27 NKTX Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
        Jun 27 NTLA Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
        Jun 26 TSVT 2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
        Jun 26 JANX Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy
        Jun 26 NTLA Intellia Therapeutics appoints CFO
        Jun 26 NTLA Intellia Therapeutics Announces CFO Transition
        Jun 26 CARM Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
        Jun 26 NTLA First-of-its-kind Intellia data suggest CRISPR drug could be given more than once
        Jun 25 NTLA Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
        Jun 25 CARM Carisma Therapeutics granted FDA fast track designation for its solid tumors treatment
        Jun 25 NTLA 3 Gene Editing Stocks That Could Make Your Grandchildren Rich
        Jun 25 CARM Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
        Jun 25 CARM Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
        Related Industries: Biotechnology
        Related Stock Lists: Medicine Immune System Biopharmaceutical Biotechnology Cancer Chimeric Antigen Receptor Clinical Medicine Solid Tumors Antigen Biology Cancer Immunotherapy Cancer Treatment Cell Therapy Life Sciences Natural Killer Cell Breakthrough Therapy CD19 Disease Emerging Technologies Gene Therapy
        Chimeric Antigen Receptor T Cell

        Chimeric Antigen Receptor T Cell (CAR-T) is a type of immunotherapy that uses a patient’s own T cells to fight cancer. The T cells are genetically modified to express a special receptor, called a chimeric antigen receptor (CAR), which is designed to recognize and bind to a specific protein found on the surface of cancer cells. Once the CAR-T cells bind to the cancer cells, they can kill them. CAR-T therapy has been used to treat certain types of blood cancers, such as leukemia and lymphoma, and is being studied for other types of cancer.

        Browse All Tags